Vitamin D Supplementation as an Adjunct Treatment for Asthma by Marshall, Robert
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-8-2015
Vitamin D Supplementation as an Adjunct
Treatment for Asthma
Robert Marshall
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Marshall, Robert, "Vitamin D Supplementation as an Adjunct Treatment for Asthma" (2015). School of Physician Assistant Studies.
Paper 535.
Vitamin D Supplementation as an Adjunct Treatment for Asthma
Abstract
Background: Asthma is a significant health problem that is trending up in prevalence and cost. The
pathophysiology of asthma has been shown to be multi-factorial. In recent years vitamin D has demonstrated
potential therapeutic benefit. Vitamin D is thought to have an effect on immune function decreasing
inflammation; as a result vitamin D may have a role in asthma management. Despite many studies linking
vitamin D with asthma very few studies have looked at treatment response following supplementation. This
review attempts to look at the effects of using oral vitamin D, in addition to standard therapy, to gain better
control of asthma.
Method: An exhaustive search was performed using Medline-Ovid, Medline-Pub-Med, Web of Science, and
Google Scholar. Keywords included were as follows: asthma, vitamin D, supplementation or dietary
supplements, and airway functions or respiratory functions. Relevant articles were assessed for quality using
GRADE.
Results: Two randomized, open-label studies and one randomized, blinded study met inclusion criteria. All
three studies demonstrated a benefit in measured airway functions and outcomes specific to each study were
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Conclusion: Vitamin D has the potential to play a significant role in the overall management of a patient with
asthma. These studies have laid the groundwork and strengthened the hypothesis that standard treatment
with supplementation of vitamin D may reduce morbidity. Despite the need for stronger, more complete
studies vitamin D is a safe adjunct therapy for asthma patients.
Keywords: Asthma, vitamin D, supplementation, dietary supplements, airway function, and respiratory
functions tests.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
First Advisor
David Keene, MPAS, PA-C
Keywords
Asthma, vitamin D, supplementation, dietary supplements, airway function, and respiratory functions tests.
Subject Categories
Medicine and Health Sciences
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/535
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/535
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/535
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
  1 
Vitamin D Supplementation as an Adjunct Treatment 
for Asthma 
 
 
 
 
 
 
 
 
Robert Marshall 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR  
For the Masters of Science Degree, August 2015 
 
Faculty Advisor: David Keene, PA-C 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
 
 
 
  2 
Biography 
[Redacted for privacy]
  3 
 
Abstract   
Background: Asthma is a significant health problem that is trending up in prevalence 
and cost. The pathophysiology of asthma has been shown to be multi-factorial. In recent 
years vitamin D has demonstrated potential therapeutic benefit. Vitamin D is thought to 
have an effect on immune function decreasing inflammation; as a result vitamin D may 
have a role in asthma management. Despite many studies linking vitamin D with asthma 
very few studies have looked at treatment response following supplementation. This 
review attempts to look at the effects of using oral vitamin D, in addition to standard 
therapy, to gain better control of asthma. 
 
Method: An exhaustive search was performed using Medline-Ovid, Medline-Pub-Med, 
Web of Science, and Google Scholar. Keywords included were as follows: asthma, 
vitamin D, supplementation or dietary supplements, and airway functions or respiratory 
functions. Relevant articles were assessed for quality using GRADE. 
 
Results: Two randomized, open-label studies and one randomized, blinded study met 
inclusion criteria. All three studies demonstrated a benefit in measured airway functions 
and outcomes specific to each study were all shown to confirm vitamin D’s role in 
asthma management. Overall the qualities of the study were moderate to low warranting 
further study with a greater amount of participants and a focus on correlating serum 
vitamin D levels with therapeutic benefit. 
 
Conclusion: Vitamin D has the potential to play a significant role in the overall 
management of a patient with asthma. These studies have laid the groundwork and 
strengthened the hypothesis that standard treatment with supplementation of vitamin D 
may reduce morbidity. Despite the need for stronger, more complete studies vitamin D is 
a safe adjunct therapy for asthma patients. 
 
Keywords: Asthma, vitamin D, supplementation, dietary supplements, airway function, 
and respiratory functions tests. 
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Vitamin D Supplementation as an Adjunct Treatment for Asthma 
 
BACKGROUND 
 
 Asthma is a major health problem in the United States, affecting over 25 million 
people in 2012, according to the Center for Disease Control and Prevention.1 It is 
estimated that asthma accounts for over 14 million outpatient visits and 500 000 
hospitalizations yearly in the U.S. Of the 2 million emergency room visits in the U.S. 
yearly, asthma is responsible for 25% and in 2007 was estimated to cost over 56 billion in 
medical costs, lost work, missed school, and early deaths.1,2 Globally, evidence has 
shown asthma prevalence to be greatest in developed countries, such as the UK, 
Australia, North, and South America.3,4 However, as developing countries begin to 
become more westernized and urbanized, the problem of asthma is beginning to increase 
in many of these regions.5,6 Despite medical advancements made towards more effective 
treatments, the problem of asthma continues to increase in prevalence.7 In recent years 
epidemiologic studies8,9  have linked vitamin D deficiency with an increase of asthma 
symptoms.  
 According to the Global Initiative for Asthma (GINA),10 asthma is defined as a 
chronic inflammatory disease of the airways resulting in bronchial constriction, hyper-
responsiveness, and excessive mucus formation.10 Anti-inflammatory medications (eg, 
corticosteroids) are the mainstay of treatment against asthma considering inflammation is 
the key element in the pathophysiology of the disease. Vitamin D has demonstrated anti-
inflammatory properties in many tissues, including lung tissue. It is theorized that vitamin 
D decreases certain proinflammatory molecules and mediators that attract and recruit 
various immune cells.11 Also, there is a study12 suggesting low vitamin D levels might 
  7 
inhibit corticosteroid signaling pathways; therefore playing a critical role in corticosteroid 
resistance and overall control of asthma. 
 There has been numerous studies13-16 correlating lower serum 25-hydroxy-vitamin 
D with worse asthma control, decreased lung function, reduced corticosteroid response, 
more frequent exacerbations, and increased corticosteroid use, suggesting that 
supplementation of vitamin D levels in patients with asthma may improve several factors 
of asthma severity and treatment response. One prospective prebirth cohort study17 
looking at higher maternal intake of vitamin D during pregnancy found that those with 
higher intake of vitamin D during pregnancy decreased the risk of wheezing in early 
childhood. Despite adequate epidemiologic studies linking vitamin D and asthma, there 
are few studies evaluating the affect of vitamin D supplementation on asthmatic patients. 
If vitamin D has the potential to play either a preventative or protective role against 
asthma, then supplementation could become part of standard therapy. This systematic 
review looks to answer the question; in asthmatic patients does the supplementation of 
oral vitamin D as an adjunct to standard therapy improve lung function when compared 
to standard therapy alone? 
METHODS 
 An exhaustive search of available literature was performed using Medline-OVID, 
Medline-Pub-Med, Web of Science, and Google Scholar. Keywords used included: 
asthma, vitamin D, supplementation or dietary supplements, and airway function or 
respiratory functions tests. Additionally, the bibliographies of the studies were searched 
further for other pertinent sources. The search was then limited to include only studies 
done on humans and in the English language. Using the Grading of Recommendations, 
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Assessment, Development, and Evaluation (GRADE),18 all relevant articles were 
assessed for quality. 
RESULTS 
 A total of 11 articles were reviewed for relevancy. After this review, three articles 
were shown to meet inclusion criteria. These articles included one double-blinded, 
randomized trial19 and two open-labeled, randomized comparative trials.20, 21 See Table I. 
Yadav et al 
 In this randomized, double blinded, placebo-controlled trial19 researchers sought 
to investigate the therapeutic role of vitamin D supplementation in children with 
moderate to severe asthma in addition to standard therapy.  Children were recruited from 
the respiratory and asthma clinic at Sharma University of Health Sciences in Rohtak, 
India. To be included in the study children had to have a diagnosis of moderate to severe 
asthma and be between 3-14 years in age. Children were excluded if they were currently 
on immunotherapy or anti IgE, had a history of premature birth (ie, <36 weeks gestation), 
required home oxygen use, had non-wheezy asthma, or showed clinical signs of vitamin 
D deficiency (eg, bony deformities or hypocalcemic symptoms).19 
 A total of 100 asthmatic children who met the above criteria were randomized 
into two groups: the placebo group (n = 50) and the vitamin D group (n = 50). In addition 
to standard therapy, the placebo group received placebo powder in the form of glucose 
sachet and the vitamin D group received 60 000 IU of oral vitamin D3 per month for 6 
months. Out of the 100 recruited patients, 10 from the placebo group and 8 from the 
vitamin D group were lost to follow up. Therefore, 82 patients completed the study. 
Overall, the groups were prognostically balanced with exception to the mean age of onset 
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of asthma, which was much higher in the placebo group.19 
 Randomization was done using sealed opaque envelope method. This was a 
double-blinded study, so both the researchers and the participants did not know which 
treatment group they were in. The primary outcome of the study was to measure the 
change in the level of severity of asthma according to GINA guidelines. Secondary 
outcomes measured were as follows: number of exacerbations during treatment period, 
change in the peak expiratory flow rate (PEFR), change in the steroid dosage, change in 
level of control, and number of emergency visits. Patients were required to follow up 
every month for 6 months in order to record the necessary outcomes.19 
 For the following results a P value < 0.05 represents statistical significance. After 
5 months there was no increase in asthma severity seen in the vitamin D group, while 
there was a small increase in asthma severity seen in the placebo group; this difference 
was not statistically significant. However, at 6 months the vitamin D group showed 
improvement in asthma severity that was statistically significant (P = 0.016). See Table 
II. There was statistically significant reduction in acute exacerbations seen in the vitamin 
D group compared to the placebo group (P = 0.011). See Table III. Significant 
improvement in the PEFR can be seen in both groups at all follow up visits up to 6 
months, however the improvement made by the vitamin D group was significantly higher 
than the placebo group (P = 0.000). See Fig. I. Regarding change in steroid dosage, a 
statistically significant decrease in steroid dosing can be seen in the vitamin D group 
when compared to the placebo group (P = 0.013). See Fig. II. When looking at asthma 
control, both groups achieved control after 4 months of treatment, however at one month 
35 patients in the vitamin D group were well controlled compared to 21 in the placebo 
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group (relative risk of 1.67 and a number-needed-to-treat of 4, P = 0.005). See Table IV. 
Lastly, in the first 3 months of treatment the number of emergency room visits 
demonstrated a statistically significant difference in favor of the vitamin D group (P = 
0.015). After the first 3 months of treatment no patients in either group were seen in the 
emergency room for asthma.19 See Table V. 
 The authors discussed two limitations. Firstly, not including measurements of 
serum vitamin D levels prior, during, and after the study was a major limitation to this 
study. Next, following the patients for a longer period of time would increase the 
significance of their findings.19 
Nageswari et al 
 This open labeled, randomized comparative trial20 investigated the effect of 
vitamin D3 supplementation in patients with mild to moderate persistent asthma by 
measuring the improvement in forced expiratory volume in 1 second (FEV1). Patients 
were recruited from SRM Medical College Hospital and Research center in Tamil Nadu, 
India. Patients were required to be between 35-65 years old without comorbidities and 
have a diagnosis of mild to moderate persistent asthma at the time of the study. Patients 
were excluded from the study if they had a history of cardiac disorders, chronic 
obstructive pulmonary disease (COPD), hepatic or renal dysfunction, intolerance to 
vitamin D supplementation, or were currently pregnant or lactating. There were 63 
patients who satisfied the above study criteria and were randomized into two groups: the 
usual care group (n=31) and the intervention care group (n=32). The groups were 
prognostically balanced with respect to age, BMI, gender, and education. Seven days 
prior to the study all patients were asked to stop using their prescribed anti-asthmatic 
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medications and use a salbutamol inhaler as rescue medication during that seven days. 
The usual care group patients received 400 µg of budesonide with 24 µg of formoterol 
daily by inhaler. The intervention care group received the same medications as the usual 
care group plus were instructed to take one 1000 IU vitamin D3 tablet orally every day. 
Patients in both groups were given permission to use a short acting β-agonist if having an 
acute asthma exacerbation.20  
 Randomization was done using a computerized system. This was an open-label 
study, so both the researchers and the participants knew which treatment they were being 
administered. The primary outcome of the study was to measure pulmonary function by 
spirometry, specifically looking at the FEV1. This was measured at baseline and each 
scheduled follow-up: day 30, 60, and 90.20 
 Significant improvement in the FEV1 was noted at every follow up visit for both 
treatment groups. However, in the intervention group there was significant improvement 
in percentage predicted FEV1 when compared to the usual care group. In the usual care 
group the percentage improvement in FEV1 after 90 days was 4.95 with a confidence 
interval (CI) of 0.2755-9.624. In the intervention group the percentage improvement in 
FEV1 after 90 days was 7.07 with a CI of 2.469-11.67.20 This difference was not 
statistically significant when comparing the two groups. 
 The authors discussed several limitations to this study; the first being the short 
duration. With the study lasting only 90 days they were unable to account for asthma 
exacerbations in the long-term control. Secondly, the study being open-label instead of 
blinded could be seen as a weakness, however the authors were not convinced this was a 
significant limitation. Not measuring the serum level of vitamin D3 prior to the study, 
  12 
throughout, and after completion of the study was potentially the most significant 
limitation to this study.20 
Arshi et al 
 This was a prospective, randomized, open-label study21 looking at airway function 
in patients with mild to moderate persistent asthma following supplementation of vitamin 
D in addition to standard therapy. Patients were enrolled from Rasool-e-Akram Hospital 
in Tehran. To be included in the study patients needed to have a current diagnosis of 
mild-moderate persistent asthma and between 10-50 years in age. Patients were excluded 
from the study if they had a history of COPD, sarcoidosis, hyperparathyroidism, 
nephrolithiasis, active tuberculosis, intolerance to vitamin D, liver failure, renal failure, 
lymphoma, malignant tumors not in remission for more than 2 years; on current treatment 
with anticonvulsants, vitamin D, systemic corticosteroid therapy up to 3 months before 
the study; were pregnant or lactating; had baseline serum calcium level > 2.65 mmol/L; 
had an asthma exacerbation up to 3 months prior to beginning of study; were actively 
smoking; or demonstrated inappropriate use of asthma medication during the study. In an 
effort to control outcomes only native Fars, patients living in Tehran were selected, to 
eliminate known factors of vitamin D metabolism, such as skin color, diet, and exposure 
to sun.21 
 A total of 130 patients that met the above study criteria participated in the study. 
These patients were randomized into two groups; the control group (n=66) and the 
intervention group (n=64). Based on stage of asthma, the control group either was given 
budesonide alone or budesonide plus formoterol, both in the form of dry powder inhaler. 
The intervention group received the same medications as the control group plus a bolus 
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dose of 100 000 U of vitamin D intramuscularly followed by 50 000 U of oral vitamin D 
pearls weekly. There were 22 patients who were lost to follow up; therefore, a total of 
108 patients completed the study.21 
 Randomization was done using consecutive random selection. Prior to 
randomization variables considered were as follows; age, sex, body mass index (BMI), 
stage of asthma, history of atopic dermatitis, allergic rhinitis, food allergy, serum IgE, 
FEV1, ratio of FEV1 to FVC, and serum vitamin D. There was no significant difference 
between the two groups with respect to these variables. This was an open-label study, so 
both researchers and participants knew which treatment they were being administered. 
The primary outcome of the study was to measure airway function by spirometry, using 
the FEV1 and the ratio of FEV1 to forced vital capacity (FVC). They also looked at the 
correlation between serum 25-hydroxy-vitamin D levels and the FEV1 and the correlation 
between ∆ vitamin D and ∆ FEV1. All outcomes were measured at baseline, 8, and 24 
weeks.21  
 For the following results a P value < 0.05 represents statistical significance. After 
8 weeks, the FEV1 had a significant improvement in both groups (P = 0.001 in the control 
group and P < 0.001 in the intervention group), but when comparing the two groups there 
was no significant difference (P = 0.16). After 24 weeks, only the intervention group had 
a significant improvement in FEV1 (P < 0.001 in the intervention group and P = 0.64 in 
the control group), so when comparing the two groups the FEV1 was significantly higher 
in the intervention group (P < 0.001). When looking at the FEV1/FVC ratio, the 
intervention group had significant improvement after 8 and 24 weeks (P = 0.002 after 8 
weeks and P = 0.001 after 24 weeks). The control group only had significant 
  14 
improvement in the FEV1/FVC ratio after 24 weeks (P = 0.48 after 8 weeks and P = 
0.001 after 24 weeks). This reveals no significant difference between the two groups with 
respect to FEV1/FVC ratio (P = 0.73 after 8 weeks and P = 0.06 after 24 weeks). Lastly, 
in looking at the correlation between serum vitamin D and FEV1, it can be seen there was 
a positive correlation between the two prior to the study beginning (P = 0.001, r = 0.272). 
Then, after 8 weeks of treatment, a negative correlation is seen between vitamin D and 
FEV1 without any significant difference (P = 0.25, r = -0.063). However, after 24 weeks 
the data shows again a positive correlation between the two with a significant difference 
(P < 0.001, r = 0.336). Also, the researchers decided to look at the correlation between ∆ 
serum vitamin D and ∆ FEV1 after 8 and 24 weeks. The results show a positive 
correlation after both 8 and 24 weeks with only a significant difference seen after 24 
weeks (P=0.33, r = 0.092 after 8 weeks and P < 0.001, r = 0.543 after 24 weeks).21 
 The authors found the most important limitations of this study to be the small 
sample size and the high mean BMI of the patients included in the study. However, there 
was not a significant difference between the two groups with respect to BMI. Another 
limitation discussed was not using a placebo for parallel control.21 
DISCUSSION 
 There are approximately 300 million people worldwide currently living with 
asthma and if current trends continue, it is estimated this number may increase to 400 
million by the year 2025.2 The United States along with other countries is bound to feel 
the increasing burden in providing care for asthmatic patients. Today, evidence suggests 
that inhaled corticosteroids are the best treatment option for asthmatics,22 however 
evidence also shows that this current recommended pharmacotherapy for asthma is not 
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achieving optimal asthma control.23,24 There have been numerous studies14-16,25-29 linking 
low levels of serum vitamin D with negative outcomes for patients with asthma. Despite 
sufficient evidence linking vitamin D with asthma, there is a limited amount of studies 
actually looking at the therapeutic role of vitamin D supplementation as an adjunct to 
asthma treatment. 
 This systematic review attempted to uncover three such studies19-21 that measured 
lung function following administration of vitamin D supplementation to standard therapy. 
Despite differences in length of study conducted and outcomes measured between the 
three studies, all three studies provided support that overall lung function improved with 
the addition of vitamin D to standard therapy. The articles when looked at collectively 
further supported each other’s findings, but also confirmed certain limitations to each 
study. 
All three studies had limitations related to the lack of diversity in regard to the  
participants. Specifically, when looking at the age of included participants in these three 
studies, only one19 had included young children. Yadav et el19 looked solely at the effects 
of vitamin D supplementation in children, aged 3-14 years old. While Nageswari et al20 
included patients ranging from 35-65 years old, and Arshi et al21 included patients 
ranging from 10-50 years old. This clearly is a limitation for both of these studies. 
Separating groups based on age would benefit future studies to determine what effect age 
may play in response to vitamin D supplementation. Also, a limitation that all three of 
these studies share is a lack of ethnic diversity among participants. Two studies19,20 
included only patients from India and one study21 included only native Fars from Tehran. 
On a global scale, future studies would prove more beneficial if including a wide variety 
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of ethnic backgrounds to determine the differences in response to treatment based on 
ethnicity. 
 While the study conducted by Nageswari et al reported a greater improvement in 
the FEV1 in the intervention group compared to the usual care group (7.07% increase vs. 
4.95% increase) after 3 months, this improvement was not statistically significant.20 After 
reviewing the other two articles, 19,21 it can be seen that this study running a duration of 3 
months was a major limitation. Arshi et al reported no difference between the two groups 
after 8 weeks, with respect to FEV1 and correlation between serum 25-hydroxy-vitamin 
D levels and the FEV1. It was only after 24 weeks that a significant difference can be 
seen between the two groups.21 Likewise, the Yadav et al study showed similar findings. 
Outcomes of asthma severity, change in PEFR, and change in steroid dosage all began to 
show statistical significance in improvement after 5 months of treatment when compared 
to the control group.19 Various studies30-32 have demonstrated that different functions of 
vitamin D begin having their effect at different serum levels and looking at evidence from 
these three studies19-21 it is easy to hypothesize that it may take time for the body to reach 
a therapeutic level to see the desired effects of vitamin D. For this reason the Nageswari 
et al study and future studies would benefit from a longer treatment period. 
 Only one study21 measured the serum vitamin D levels prior to administration and 
at follow-ups. This was a major limitation for both the Yadav et al and Nageswari et al 
studies. Arshi et al reported positive and significant correlation after 24 weeks between 
serum vitamin D and FEV1, as well ∆ vitamin D and ∆ FEV1. Measurements of serum 
vitamin D levels allows for better control of variability within the study and provides 
evidence as to the appropriate serum vitamin D level to see the positive impact. Future 
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studies would be strengthened by measuring serum vitamin D levels throughout, as well 
as giving different doses of vitamin D to each group to determine the best effective dose 
of vitamin D. 
 Despite the limitations discussed previously and the need for stronger future 
studies, clinicians would not be taking any great risks, along as toxic levels of vitamin D 
are avoided, in applying the information gathered in these studies to their patients. Based 
upon the information gathered from all three studies it seems reasonable to supplement 
asthmatic patients with vitamin D at a starting dose greater than the recommended 600-
800 IU daily33 and to assume that benefit is most likely noted after 6 months of therapy. 
Care should be taken prior to supplementation in that the patient vitamin D levels should 
be assessed, risk factors should be reviewed, and toxic doses should be avoided. 
Supplementation with vitamin D as adjunct to standard therapy is a safe and inexpensive 
option.34 For this reason, clinicians could enter into discussion with certain patients that 
may benefit from vitamin D supplementation as an adjunct to standard therapy. 
CONCLUSION 
Vitamin D has been demonstrated to have a significant role in the management of 
mild to severe asthma as an adjunct to standard treatment. Supplementing asthmatics with 
vitamin D has the potential to impact overall morbidity in a positive way. Despite the 
promising evidence established by these three studies, they were unable to assist in 
setting clear treatment guidelines that can be implemented in clinic practice today. These 
studies only further supported the need for improved future studies that include larger, 
randomized, placebo controlled trials. However, due to the low cost, low risk, and 
potential benefits of vitamin D supplementation as an adjunct treatment, it could be 
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considered for patients who are willing. 
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TABLE I:  Grade evidence profile: Vitamin D supplementation as an adjunct treatment for asthmatics 
 
 
 
 
 a. Did not assess vitamin D levels 
 b: Lack of allocation concealment 
 c: Lack of blinding 
 d: Length of study is less than 6 months 
 e: Lack of representation of diverse ethnicities  
Quality Assessment  
 Downgrade Criteria 
Quality 
 Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Yadav et al19  
 
 RCT Serious
a,b Not Serious Not serious Not serious No bias likely Moderate 
Nageswari et al20  
 RCT Very Seriousa,b,c,d,e Not serious Not serious Not serious 
No bias 
likely Low 
Arshi et al21  
 RCT 
 
Very 
Seriousb,c,d,e 
 
Not serious Not serious Not serious No bias likely Low 
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Summary of Findings 
 
Table II: Level of severity of the patients in the two groups (Yadav et al19) 
 
 
Table III: Number of exacerbations during treatment period (Yadav et al19) 
 
 
 
Fig. I: Mean PEFR in the two groups (Yadav et al19) 
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Fig. II: Mean steroid dose in the patients of the two treatment groups (Yadav et al19) 
 
 
Table IV: Level of control of the patients in the two groups (Yadav et al19) 
 
 
Table V: Mean number of emergency visits of the patients in the two groups (Yadav et al19)  
 
 
 
